Trusted Resources: People & Places
Online groups, photo galleries and blogs
Paul Orchard, MD
Healthcare Professional Director
Mucopolysaccharidosis (MPS) Center
University of Minnesota
660B Masonic Cancer Research Building
425 East River Parkway
Minneapolis, Minnesota, United States
Dr. Paul Orchard is the Medical Director of the Inherited Metabolic and Storage Disease Program and a Professor in the Department of Pediatrics, Division of Blood and Marrow Transplant & Cellular Therapy. Dr. Orchard’s focus is in the use of hematopoietic stem cell transplantation and other cell therapies for inherited metabolic disorders, with a special interest in the inherited Leukodystrophies, the Mucopolysaccharidoses and Osteopetrosis. His clinical research is in evolving new and combination therapies to decrease toxicity and improve outcomes, with a particular interest in the use of gene therapy approaches.
Dr. Paul Orchard completed his MD from Brown University Hospital, Residency in Pediatrics from University of Wisconsin Hospital, and Fellowship in Hematology-Oncology and Blood and Marrow Transplantation from the University of Minnesota Medical School. He serves as the Director of Mucopolysaccharidosis (MPS) Center, University of Minnesota.
Representative Publications:
Differences in MPS I and MPS II Disease Manifestations
Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
Treatment of Brain Disease in the Mucopolysaccharidoses
Unique Medical Issues in Adult Patients With Mucopolysaccharidoses
Related Content
-
Combined Aortic and Mitral Valve Stenosis in Mucopolysaccharidosis Syndrome Type I-S: A Report of a Rare CaseMucopolysaccharidosis (MPS) syndrome is ...
-
Enzyme Replacement Therapy With Galsulfase for Mucopolysaccharidosis Type VIMucopolysaccharidosis type VI (MPS VI) o...
-
Expanding the Phenotype of Mucopolysaccharidosis Type II RetinopathyPurpose: To report novel retinal finding...
-
MPS 1: Where Are We NowDr. Sandra Kingma from the Centre for Ra...
-
The Youngest Pair of Siblings With Mucopolysaccharidosis Type IVA to Receive Enzyme Replacement Therapy to Date: A C...Mucopolysaccharidosis type IVA (OMIM 253...
-
[Pharmacological Property, Mechanism of Action and Clinical Study Results of Pabinafusp Alfa (Genetical Recombinatio...Mucopolysaccharidosis type II (MPS II) i...
-
The Ryan FoundationChildren with rare diseases are racing t...